Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. Perrigo Company ( PRGO) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.4%. By the end of trading, Perrigo Company rose $1.17 (1.2%) to $100.51 on heavy volume. Throughout the day, 1.5 million shares of Perrigo Company exchanged hands as compared to its average daily volume of 745,600 shares. The stock ranged in a price between $99.08-$100.99 after having opened the day at $99.47 as compared to the previous trading day's close of $99.34. Other companies within the Health Care sector that increased today were: ARCA biopharma ( ABIO), up 26.5%, Redhill Biopharma Ltd ADR ( RDHL), up 23.6%, Cardiovascular Systems ( CSII), up 15.7%, and EntreMed ( ENMD), up 13.9%.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API) worldwide. Perrigo Company has a market cap of $9.51 billion and is part of the drugs industry. The company has a P/E ratio of 21.8, above the S&P 500 P/E ratio of 17.7. Shares are down 4.6% year to date as of the close of trading on Wednesday. Currently there are seven analysts that rate Perrigo Company a buy, one analyst rates it a sell, and eight rate it a hold. TheStreet Ratings rates Perrigo Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.